<DOC>
	<DOC>NCT02867735</DOC>
	<brief_summary>To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Patients with macular edema with center involvement in at least one eye, including those with focal or diffuse DME, neovascular AMD, or RVO The ETDRS letter score in the study eye must be 60 letters or worse (approximate Snellen equivalent of 20/63) Vital signs as specified within the protocol Proliferative diabetic retinopathy in the study eye, with the exception of tufts of neovascularization less than one disc area with no vitreous hemorrhage Patient, with type 1 or type 2 diabetes who have a hemoglobin A1C &gt; or = 12% at screening other ocular conditions as specified in the protocol systemic conditions as specified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>Diabetic Macular Edema (DME)</keyword>
	<keyword>Neovascular age-related Macular Degeneration(AMD)</keyword>
	<keyword>Retinal Vein Occlusions(RVO)</keyword>
</DOC>